Clinical trial
The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder
NCT00249236 is registered in ClinicalTrials.gov with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy And Safety Of Flexible Dosage Ranges Of Risperidone Versus Placebo In The Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2001
- Completion date
- December 31, 2001
- Enrollment
- 291 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
bipolar disorder, manic episode